Literature DB >> 35247893

Glioblastoma: The Current State of Biology and Therapeutic Strategies.

Zev A Binder1,2,3, Donald M O'Rourke1,2,3.   

Abstract

Over the past two decades, there have been advances in surgical technologies and chemoradiation strategies for glioblastoma, yet durable remissions are rarely seen. As the biological challenges and genetic basis of glioblastoma have become more understood, new therapeutic strategies may lead to more durable clinical responses and long-term remissions. We believe specialized academic centers that form meaningful corporate partnerships to complement basic science infrastructure and use adaptive clinical trial designs will achieve more rapid translation of innovative approaches to glioblastoma. Here we outline the core biological challenges to be overcome in the management of glioblastoma. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 35247893      PMCID: PMC8909691          DOI: 10.1158/0008-5472.CAN-21-3534

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  13 in total

1.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Authors:  Qianghu Wang; Baoli Hu; Xin Hu; Hoon Kim; Massimo Squatrito; Lisa Scarpace; Ana C deCarvalho; Sali Lyu; Pengping Li; Yan Li; Floris Barthel; Hee Jin Cho; Yu-Hsi Lin; Nikunj Satani; Emmanuel Martinez-Ledesma; Siyuan Zheng; Edward Chang; Charles-Etienne Gabriel Sauvé; Adriana Olar; Zheng D Lan; Gaetano Finocchiaro; Joanna J Phillips; Mitchel S Berger; Konrad R Gabrusiewicz; Guocan Wang; Eskil Eskilsson; Jian Hu; Tom Mikkelsen; Ronald A DePinho; Florian Muller; Amy B Heimberger; Erik P Sulman; Do-Hyun Nam; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

2.  Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity.

Authors:  Laura M Richards; Owen K N Whitley; Graham MacLeod; Florence M G Cavalli; Fiona J Coutinho; Julia E Jaramillo; Nataliia Svergun; Mazdak Riverin; Danielle C Croucher; Michelle Kushida; Kenny Yu; Paul Guilhamon; Naghmeh Rastegar; Moloud Ahmadi; Jasmine K Bhatti; Danielle A Bozek; Naijin Li; Lilian Lee; Clare Che; Erika Luis; Nicole I Park; Zhiyu Xu; Troy Ketela; Richard A Moore; Marco A Marra; Julian Spears; Michael D Cusimano; Sunit Das; Mark Bernstein; Benjamin Haibe-Kains; Mathieu Lupien; H Artee Luchman; Samuel Weiss; Stephane Angers; Peter B Dirks; Gary D Bader; Trevor J Pugh
Journal:  Nat Cancer       Date:  2021-01-04

3.  ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.

Authors:  Víctor A Arrieta; Andrew X Chen; J Robert Kane; Seong Jae Kang; Cynthia Kassab; Crismita Dmello; Junfei Zhao; Kirsten B Burdett; Pavan S Upadhyayula; Catalina Lee-Chang; Joseph Shilati; Dinesh Jaishankar; Li Chen; Andrew Gould; Daniel Zhang; Jinzhou Yuan; Wenting Zhao; Xiaoyang Ling; Jared K Burks; Brice Laffleur; Christina Amidei; Jeffrey N Bruce; Rimas V Lukas; Jonathan T Yamaguchi; David Cieremans; Gerson Rothschild; Uttiya Basu; Matthew McCord; Daniel J Brat; Hui Zhang; Lee A D Cooper; Bin Zhang; Peter Sims; Tim F Cloughesy; Robert Prins; Peter Canoll; Roger Stupp; Amy B Heimberger; Craig Horbinski; Fabio M Iwamoto; Raul Rabadan; Adam M Sonabend
Journal:  Nat Cancer       Date:  2021-11-29

4.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Authors:  Donald M O'Rourke; MacLean P Nasrallah; Arati Desai; Jan J Melenhorst; Keith Mansfield; Jennifer J D Morrissette; Maria Martinez-Lage; Steven Brem; Eileen Maloney; Angela Shen; Randi Isaacs; Suyash Mohan; Gabriela Plesa; Simon F Lacey; Jean-Marc Navenot; Zhaohui Zheng; Bruce L Levine; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus
Journal:  Sci Transl Med       Date:  2017-07-19       Impact factor: 17.956

5.  The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.

Authors:  Timothy D Martin; Rupesh S Patel; Danielle R Cook; Mei Yuk Choi; Ajinkya Patil; Anthony C Liang; Mamie Z Li; Kevin M Haigis; Stephen J Elledge
Journal:  Science       Date:  2021-09-16       Impact factor: 47.728

6.  Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization.

Authors:  Ana Rita Pombo Antunes; Isabelle Scheyltjens; Francesca Lodi; Julie Messiaen; Asier Antoranz; Johnny Duerinck; Daliya Kancheva; Liesbet Martens; Karen De Vlaminck; Hannah Van Hove; Signe Schmidt Kjølner Hansen; Francesca Maria Bosisio; Koen Van der Borght; Steven De Vleeschouwer; Raf Sciot; Luc Bouwens; Michiel Verfaillie; Niels Vandamme; Roosmarijn E Vandenbroucke; Olivier De Wever; Yvan Saeys; Martin Guilliams; Conny Gysemans; Bart Neyns; Frederik De Smet; Diether Lambrechts; Jo A Van Ginderachter; Kiavash Movahedi
Journal:  Nat Neurosci       Date:  2021-03-29       Impact factor: 28.771

7.  Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.

Authors:  Saima Rathore; Hamed Akbari; Martin Rozycki; Kalil G Abdullah; MacLean P Nasrallah; Zev A Binder; Ramana V Davuluri; Robert A Lustig; Nadia Dahmane; Michel Bilello; Donald M O'Rourke; Christos Davatzikos
Journal:  Sci Rep       Date:  2018-03-23       Impact factor: 4.379

8.  Electrical and synaptic integration of glioma into neural circuits.

Authors:  Humsa S Venkatesh; Wade Morishita; Anna C Geraghty; Dana Silverbush; Shawn M Gillespie; Marlene Arzt; Lydia T Tam; Cedric Espenel; Anitha Ponnuswami; Lijun Ni; Pamelyn J Woo; Kathryn R Taylor; Amit Agarwal; Aviv Regev; David Brang; Hannes Vogel; Shawn Hervey-Jumper; Dwight E Bergles; Mario L Suvà; Robert C Malenka; Michelle Monje
Journal:  Nature       Date:  2019-09-18       Impact factor: 49.962

9.  Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.

Authors:  Ester Gangoso; Benjamin Southgate; Leanne Bradley; Stefanie Rus; Felipe Galvez-Cancino; Niamh McGivern; Esra Güç; Chantriolnt-Andreas Kapourani; Adam Byron; Kirsty M Ferguson; Neza Alfazema; Gillian Morrison; Vivien Grant; Carla Blin; IengFong Sou; Maria Angeles Marques-Torrejon; Lucia Conde; Simona Parrinello; Javier Herrero; Stephan Beck; Sebastian Brandner; Paul M Brennan; Paul Bertone; Jeffrey W Pollard; Sergio A Quezada; Duncan Sproul; Margaret C Frame; Alan Serrels; Steven M Pollard
Journal:  Cell       Date:  2021-04-09       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.